Ikena Oncology has been granted a patent for MEK inhibitors, compositions, and methods of use. The compound selection is a key aspect of the patent claim. GlobalData’s report on Ikena Oncology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Ikena Oncology, Cancer treatment biomarkers was a key innovation area identified from patents. Ikena Oncology's grant share as of January 2024 was 10%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11878958B2) discloses a series of claims related to a compound and pharmaceutical composition. The claims outline the specific compound selected and its variations, along with the pharmaceutical composition containing these compounds. The patent covers a range of compounds and their pharmaceutical compositions, providing a broad scope for potential applications in the medical field.
The claims specify the compound selected and its variations, highlighting the potential for diverse applications in pharmaceutical compositions. The patent emphasizes the importance of these compounds in the development of new medications or treatments. By outlining the specific compounds and their pharmaceutical compositions, the patent offers valuable insights for researchers and professionals in the healthcare industry. Overall, the granted patent (Publication Number: US11878958B2) provides a comprehensive overview of the compound and pharmaceutical composition, paving the way for future innovations and advancements in the field of medicine.
To know more about GlobalData’s detailed insights on Ikena Oncology, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.